Navigating the noise – conversations with the Natixis Investment Managers Expert Collective.

Why has ResMed rocketed up and is the ride over?

Shareholders of Resmed have been on a rollercoaster ride in the past year. Late last year, after news of the efficacy of Ozempic and other GLP-1 drugs came to light, the Resmed share price dropped as investors grew concerned about the potential impact on Resmed’s business. But since then it has steadily made up lost ground and is now trading at similar levels.

But what has driven the share price appreciation?
Has the Ozempic effect hit yet?
And does Resmed’s rally have further to go?

In our latest podcast, IML’s Senior Equity Analyst Bruce Du, gives his perspective.

Broadcast on:: 13 May 2024

Shareholders of ResMed have been on a rollercoaster ride in the past year. Late last year, after news of the efficacy of Ozempic and other GLP-1 drugs came to light, the ResMed share price dropped as investors grew concerned about the potential impact on ResMed’s business. But since then it has steadily made up lost ground and is now trading at similar levels.

But what has driven the share price appreciation?
Has the Ozempic effect hit yet?
And does ResMed’s rally have further to go?

In our latest podcast, IML’s Senior Equity Analyst Bruce Du, gives his perspective.